ProfileGDS5678 / 1433659_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 80% 79% 80% 82% 81% 79% 78% 81% 81% 80% 79% 77% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6775180
GSM967853U87-EV human glioblastoma xenograft - Control 25.6289480
GSM967854U87-EV human glioblastoma xenograft - Control 35.5586779
GSM967855U87-EV human glioblastoma xenograft - Control 45.8502880
GSM967856U87-EV human glioblastoma xenograft - Control 55.9344982
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6356581
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3202979
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4124578
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7939381
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.805581
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5916880
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5687379
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2671877
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5490279